Research ExplorerPublicationsSubset of esophageal adenocarcinoma expresses adhesion molec...

Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma.

Standard

Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. / Rawnaq, Tamina; Kleinhans, Helge; Uto, Marius; Schurr, Paulus; Reichelt, Uta; Cataldegirmen, Güllü; Gawad, Karim A.; Yekebas, Emre F.; Schachner, Melitta; Izbicki, Jakob R.; Kaifi, Jussuf.

In: ANTICANCER RES, Vol. 29, No. 4, 4, 2009, p. 1195-1199.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rawnaq, T, Kleinhans, H, Uto, M, Schurr, P, Reichelt, U, Cataldegirmen, G, Gawad, KA, Yekebas, EF, Schachner, M, Izbicki, JR & Kaifi, J 2009, 'Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma.', ANTICANCER RES, vol. 29, no. 4, 4, pp. 1195-1199. <http://www.ncbi.nlm.nih.gov/pubmed/19414364?dopt=Citation>

APA

Rawnaq, T., Kleinhans, H., Uto, M., Schurr, P., Reichelt, U., Cataldegirmen, G., Gawad, K. A., Yekebas, E. F., Schachner, M., Izbicki, J. R., & Kaifi, J. (2009). Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. ANTICANCER RES, 29(4), 1195-1199. [4]. http://www.ncbi.nlm.nih.gov/pubmed/19414364?dopt=Citation

Vancouver

Rawnaq T, Kleinhans H, Uto M, Schurr P, Reichelt U, Cataldegirmen G et al. Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. ANTICANCER RES. 2009;29(4):1195-1199. 4.

Bibtex

@article{07a40ce1ad5a410c9ca968e7f9490a1d,
title = "Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma.",
abstract = "BACKGROUND: Esophageal adenocarcinoma is currently the most rapidly increasing cancer in Western populations. L1 (CD171), a neural cell adhesion molecule, has an essential function in tumor progression and has been shown to be expressed in the proliferating cells of the intestinal crypts in mice. The aim of the current study was to determine L1 expression in esophageal cancer and to evaluate whether L1 could serve as a potential marker and therapeutic target for this tumor type. MATERIALS AND METHODS: L1 expression was assessed on a tissue microarray with 257 surgically resected esophageal cancer samples by immunohistochemistry with a monoclonal antibody (Clone UJ127). L1 expression was correlated with clinicopathological data. RESULTS: L1 was detected in 22 (9%) of 257 esophageal cases, whereas 235 (91%) were L1 negative. Nineteen (86%) of the 22 L1-positive cases were adenocarcinoma. Cross table analysis showed a significant association between L1 expression and adenocarcinoma subtype (p",
author = "Tamina Rawnaq and Helge Kleinhans and Marius Uto and Paulus Schurr and Uta Reichelt and G{\"u}ll{\"u} Cataldegirmen and Gawad, {Karim A.} and Yekebas, {Emre F.} and Melitta Schachner and Izbicki, {Jakob R.} and Jussuf Kaifi",
year = "2009",
language = "Deutsch",
volume = "29",
pages = "1195--1199",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

RIS

TY - JOUR

T1 - Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma.

AU - Rawnaq, Tamina

AU - Kleinhans, Helge

AU - Uto, Marius

AU - Schurr, Paulus

AU - Reichelt, Uta

AU - Cataldegirmen, Güllü

AU - Gawad, Karim A.

AU - Yekebas, Emre F.

AU - Schachner, Melitta

AU - Izbicki, Jakob R.

AU - Kaifi, Jussuf

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Esophageal adenocarcinoma is currently the most rapidly increasing cancer in Western populations. L1 (CD171), a neural cell adhesion molecule, has an essential function in tumor progression and has been shown to be expressed in the proliferating cells of the intestinal crypts in mice. The aim of the current study was to determine L1 expression in esophageal cancer and to evaluate whether L1 could serve as a potential marker and therapeutic target for this tumor type. MATERIALS AND METHODS: L1 expression was assessed on a tissue microarray with 257 surgically resected esophageal cancer samples by immunohistochemistry with a monoclonal antibody (Clone UJ127). L1 expression was correlated with clinicopathological data. RESULTS: L1 was detected in 22 (9%) of 257 esophageal cases, whereas 235 (91%) were L1 negative. Nineteen (86%) of the 22 L1-positive cases were adenocarcinoma. Cross table analysis showed a significant association between L1 expression and adenocarcinoma subtype (p

AB - BACKGROUND: Esophageal adenocarcinoma is currently the most rapidly increasing cancer in Western populations. L1 (CD171), a neural cell adhesion molecule, has an essential function in tumor progression and has been shown to be expressed in the proliferating cells of the intestinal crypts in mice. The aim of the current study was to determine L1 expression in esophageal cancer and to evaluate whether L1 could serve as a potential marker and therapeutic target for this tumor type. MATERIALS AND METHODS: L1 expression was assessed on a tissue microarray with 257 surgically resected esophageal cancer samples by immunohistochemistry with a monoclonal antibody (Clone UJ127). L1 expression was correlated with clinicopathological data. RESULTS: L1 was detected in 22 (9%) of 257 esophageal cases, whereas 235 (91%) were L1 negative. Nineteen (86%) of the 22 L1-positive cases were adenocarcinoma. Cross table analysis showed a significant association between L1 expression and adenocarcinoma subtype (p

M3 - SCORING: Zeitschriftenaufsatz

VL - 29

SP - 1195

EP - 1199

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 4

M1 - 4

ER -